
Emma L. Barber, MD, discusses how key data from the phase 3 KEYNOTE-775 study improved the identification of patient populations within endometrial cancer that benefit from second-line immunotherapy.

Emma L. Barber, MD, discusses how key data from the phase 3 KEYNOTE-775 study improved the identification of patient populations within endometrial cancer that benefit from second-line immunotherapy.

Emma L. Barber, MD, discusses the role of molecular profiling for treatment considerations in patients with endometrial cancer.

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses the importance of the SCORPION trial in ovarian cancer.

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses neoadjuvant chemotherapy lowering readmission rates for patients with ovarian cancer.

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses neoadjuvant chemotherapy versus surgery for patients with ovarian cancer.

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses surgical readmission and survival in patients with ovarian cancer.

April 24th 2017

September 5th 2017